20.12.2016 • NewscancerCollaborationSmall Molecules

Proteros Signs Second Oncology Collaboration with MSD

Proteros Biostructures has entered into a second research agreement with Merck Sharp & Dohme (known as MSD outside the US and Canada). The new collaboration is aimed at developing small molecule compounds against an additional epigenetic target for the potential treatment of various cancers.

Under the terms of the agreement, Proteros will receive an upfront payment and research funding and will be eligible to receive development, regulatory and commercial milestone payments up to $167 million plus tiered royalties. Additional details of the collaboration were not disclosed.

Dr. Torsten Neuefeind, CEO of Proteros commented: “We are pleased to expand our relationship with MSD just one year after starting our first collaboration in epigenetic drug discovery. This new collaboration will benefit from our previous and ongoing work with the team at MSD and we look forward to a further successful partnership, which potentially could transform the treatment of many cancers.”

Company

Logo:

Merck & Co

126 East Lincoln Avenue
07065 Rahway
US

Company contact







CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.